JP2022545660A5 - - Google Patents
Info
- Publication number
- JP2022545660A5 JP2022545660A5 JP2022510915A JP2022510915A JP2022545660A5 JP 2022545660 A5 JP2022545660 A5 JP 2022545660A5 JP 2022510915 A JP2022510915 A JP 2022510915A JP 2022510915 A JP2022510915 A JP 2022510915A JP 2022545660 A5 JP2022545660 A5 JP 2022545660A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cancer
- antigen
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019101563 | 2019-08-20 | ||
| CNPCT/CN2019/101563 | 2019-08-20 | ||
| CNPCT/CN2020/097559 | 2020-06-22 | ||
| CN2020097559 | 2020-06-22 | ||
| PCT/CN2020/110220 WO2021032157A1 (en) | 2019-08-20 | 2020-08-20 | Novel anti-cldn18.2 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545660A JP2022545660A (ja) | 2022-10-28 |
| JP2022545660A5 true JP2022545660A5 (https=) | 2023-09-05 |
| JP7767270B2 JP7767270B2 (ja) | 2025-11-11 |
Family
ID=74659946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510915A Active JP7767270B2 (ja) | 2019-08-20 | 2020-08-20 | 新規抗ｃｌｄｎ１８．２抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220306765A1 (https=) |
| EP (1) | EP4017883A4 (https=) |
| JP (1) | JP7767270B2 (https=) |
| KR (1) | KR20220045040A (https=) |
| CN (1) | CN114630840B (https=) |
| AU (1) | AU2020332585A1 (https=) |
| BR (1) | BR112022003147A2 (https=) |
| CA (1) | CA3149406A1 (https=) |
| MX (1) | MX2022002111A (https=) |
| TW (1) | TW202120558A (https=) |
| WO (1) | WO2021032157A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210110339A (ko) * | 2018-12-28 | 2021-09-07 | 난징 진스크립트 바이오테크 컴퍼니 리미티드 | 클라우딘18.2 결합 모이어티 및 그 용도 |
| SG11202108398YA (en) | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| WO2022098972A1 (en) | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| US20240307564A1 (en) * | 2021-02-19 | 2024-09-19 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cldn18.2 antibody conjugates |
| CN113151211B (zh) * | 2021-03-11 | 2022-06-14 | 中国科学院合肥物质科学研究院 | 一种α-1,3-岩藻糖基转移酶突变体及利用该突变体制备3-岩藻糖基乳糖的应用 |
| US12600774B2 (en) * | 2021-05-31 | 2026-04-14 | Shijiazhuang Yiling Pharmaceutical Co., Ltd. | Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof |
| WO2023025306A1 (zh) * | 2021-08-27 | 2023-03-02 | 三优生物医药(上海)有限公司 | 靶向pd-l1和cldn18.2的双特异性抗体及其制备方法和应用 |
| JP2024540062A (ja) * | 2021-11-05 | 2024-10-31 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 抗ｃｌｄｎ１８．２抗体及びその用途 |
| CN116410326A (zh) * | 2021-12-30 | 2023-07-11 | 三优生物医药(上海)有限公司 | 抗cd40×cldn18.2双特异性抗体及其用途 |
| WO2023221935A1 (zh) * | 2022-05-17 | 2023-11-23 | 苏州创胜医药集团有限公司 | 结合pd-l1和cldn18.2的抗体及其用途 |
| TW202415407A (zh) * | 2022-06-30 | 2024-04-16 | 中國大陸商蘇州創勝醫藥集團有限公司 | 穩定之包含抗cldn18.2抗體的藥物製劑 |
| WO2024041574A1 (en) * | 2022-08-24 | 2024-02-29 | Suzhou Transcenta Therapeutics Co., Ltd. | Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates |
| CN115975032B (zh) * | 2022-12-19 | 2024-06-07 | 华润生物医药有限公司 | 一种cldn18.2抗体及其应用 |
| CN118667003A (zh) * | 2023-03-16 | 2024-09-20 | 亘喜生物科技（上海）有限公司 | 特异性结合Claudin18.2的抗体及其制法和应用 |
| CN116903745B (zh) * | 2023-09-13 | 2023-11-14 | 苏州仁端生物医药科技有限公司 | 一种抗人Claudin18.2的单克隆抗体及其应用 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| TW202541840A (zh) * | 2023-12-19 | 2025-11-01 | 大陸商蘇州創勝醫藥集團有限公司 | 包含抗ｃｌａｕｄｉｎ１８．２抗體的製劑 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| JP6499079B2 (ja) * | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US10858415B2 (en) * | 2014-01-29 | 2020-12-08 | Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh | Peptide mimotopes of claudin 18.2 and uses thereof |
| CN120518772A (zh) | 2014-07-17 | 2025-08-22 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| EP3765522A4 (en) * | 2018-03-14 | 2022-05-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODIES |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
-
2020
- 2020-08-20 JP JP2022510915A patent/JP7767270B2/ja active Active
- 2020-08-20 CN CN202080058759.9A patent/CN114630840B/zh active Active
- 2020-08-20 CA CA3149406A patent/CA3149406A1/en active Pending
- 2020-08-20 MX MX2022002111A patent/MX2022002111A/es unknown
- 2020-08-20 TW TW109128483A patent/TW202120558A/zh unknown
- 2020-08-20 US US17/636,373 patent/US20220306765A1/en active Pending
- 2020-08-20 BR BR112022003147A patent/BR112022003147A2/pt unknown
- 2020-08-20 AU AU2020332585A patent/AU2020332585A1/en active Pending
- 2020-08-20 EP EP20854013.8A patent/EP4017883A4/en active Pending
- 2020-08-20 KR KR1020227008819A patent/KR20220045040A/ko active Pending
- 2020-08-20 WO PCT/CN2020/110220 patent/WO2021032157A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545660A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| FI3882275T3 (fi) | Bifunktionaalinen anti-PD-1- ja anti-VEGFA-vasta-aine, sen farmaseuttinen koostumus ja sen käyttö | |
| JP2020510422A5 (https=) | ||
| JP2024508672A5 (https=) | ||
| JP2019519492A5 (https=) | ||
| JP2020534830A5 (https=) | ||
| JP2023539501A5 (https=) | ||
| JP2017149720A5 (https=) | ||
| JP2023527937A5 (https=) | ||
| WO2019030377A1 (en) | CD96 BINDING AGENTS AS IMMUNOMODULATORS | |
| JP2024504124A5 (https=) | ||
| JP2024515560A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JP2024513692A5 (https=) | ||
| CN110551216B (zh) | 多价抗ox40抗体及其用途 | |
| JP2023534959A5 (https=) | ||
| JP2021529524A5 (https=) | ||
| JP2024540863A5 (https=) | ||
| CN106831987B (zh) | 一种抗人her2抗体及其编码基因和应用 | |
| CN110603267A (zh) | 与p53-MHC I类复合物结合的T细胞受体样抗体 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| US20230143003A1 (en) | Affinity matured and humanized binding domains targeting ror2 | |
| JP2025535104A (ja) | Ｂ７ｈ３／ｐｄｌ１二重特異性抗体およびその医薬組成物ならびにその使用 |